NS-3 (CG3703), an analog of thyrotropin-releasing hormone, ameliorates cognitive impairment in rats

Pharmacol Biochem Behav. 1995 Apr;50(4):499-503. doi: 10.1016/0091-3057(94)00312-2.

Abstract

The effects of thyrotropin-releasing hormone (TRH) and its analog, N-[[(3R,6R)-6-methyl-5-oxo-thiomorpholinyl] carbonyl]-L-histidyl-L- prolinamide tetrahydrate (NS-3, CG3703) on disturbance of memory of a passive avoidance response (PAR) and an escape response in rats were investigated. NS-3 improved amnesia caused by scopolamine, electroconvulsive shock (ECS), and cycloheximide (CXM), but TRH improved only the ECS-induced amnesia. NS-3 reversed learning deficits caused by hypercapnia, but TRH had no effect. These differences in the effect between NS-3 and TRH may be due to their biological half-life in rat plasma. These results suggest that NS-3 possesses more potent antiamnestic effects than TRH in rats.

Publication types

  • Comparative Study

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Avoidance Learning / drug effects
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / etiology
  • Cycloheximide / antagonists & inhibitors
  • Electroshock
  • Hypercapnia / complications
  • Hypercapnia / drug therapy
  • Male
  • Molecular Sequence Data
  • Rats
  • Rats, Wistar
  • Scopolamine / antagonists & inhibitors
  • Thyrotropin-Releasing Hormone / analogs & derivatives*
  • Thyrotropin-Releasing Hormone / therapeutic use*

Substances

  • montirelin
  • Thyrotropin-Releasing Hormone
  • Cycloheximide
  • Scopolamine